Compare CarMax, Inc (KMX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? CarMax, Inc trades at $50.99 (market cap $7.07B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: CarMax, Inc is far larger — about 7.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and CarMax, Inc is more actively traded (2,330,911.51 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KMX | MRVI | |
|---|---|---|
Market Cap | $7.07B | $977.37M |
Volume | 2,330,911.51 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $9.00 |
52-Week Low | $30.88 | $2.83 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $24.77B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $50.81, showing modest daily gains of 0.24% amid bearish technical signals. The company delivered strong Q2 2027 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. Despite positive earnings momentum, the stock faces headwinds with bearish moving averages and oscillators indicating technical weakness. Recent leadership appointments and strategic updates signal management's focus on growth initiatives.
KMX presents a mixed outlook with strong fundamental performance offset by technical bearishness. The 29% upside to consensus price target of $60.63 offers potential reward, but investors face risks from declining profit margins, high debt levels, and competitive pressures in the used car market. Recent earnings beat and strategic initiatives provide catalysts, though technical indicators suggest near-term caution.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
